VALIDATED RP-UPLC METHOD DEVELOPMENT FOR ESTIMATION OF LANSOPRAZOLE IN TABLET DOSAGE FORM

Authors

  • Sunil Singh Department of Pharmaceutical Chemistry, Invertis Institute of Pharmacy, Invertis University, Bareilly, Uttar Pradesh, India
  • Nisha Choudhary Department of Pharmaceutical Chemistry, Invertis Institute of Pharmacy, Invertis University, Bareilly, Uttar Pradesh, India
  • Jyoti Rai Department of Pharmaceutical Chemistry, Invertis Institute of Pharmacy, Invertis University, Bareilly, Uttar Pradesh, India
  • Inamullah . Department of Pharmaceutical Chemistry, Invertis Institute of Pharmacy, Invertis University, Bareilly, Uttar Pradesh, India
  • Surabhi Sharma Department of Pharmaceutical Chemistry, Invertis Institute of Pharmacy, Invertis University, Bareilly, Uttar Pradesh, India
  • Ajit Kumar Yadav Department of Pharmaceutical Chemistry, Invertis Institute of Pharmacy, Invertis University, Bareilly, Uttar Pradesh, India
  • Hemendra Gautam Department of Pharmaceutical Chemistry, Invertis Institute of Pharmacy, Invertis University, Bareilly, Uttar Pradesh, India
  • Shashank Chaturvedi Department of Pharmaceutical Chemistry, Invertis Institute of Pharmacy, Invertis University, Bareilly, Uttar Pradesh, India
  • Vipin Kumar Agrawal Department of Pharmaceutical Chemistry, Invertis Institute of Pharmacy, Invertis University, Bareilly, Uttar Pradesh, India

Abstract

A simple, sensitive and precise isocratic ultra performance liquid chromatographic method for the analysis of Lansoprazole has been developed, validated and used for the determination of compounds in commercial pharmaceutical products. The separation was carried out isocratically on a C18 column utilizing a mobile phase consisting of methanol: water (80:20 v/v) at a flow rate of 1.0 mL/min with UV detection at 284 nm. The retention time of Lansoprazole was found to be 3.905 min. The described method was linear over a concentration range of 50-30 μg/ml (r2 =0∙998) for the assay of Lansoprazole. Results of analysis were validated statistically. The results of the study showed that the proposed RP-UPLC method is simple, rapid, precise and accurate, which is useful for the routine determination of Lansoprazole in tablet dosage form and in its pharmaceutical dosage forms.

Keywords:

Lansoprazole, RP-UPLC, Method validation and Tablets

DOI

https://doi.org/10.25004/IJPSDR.2013.050305

References

1. Brummer RJ, Geerling BJ, Stockbrugger RW. Initial and chronic gastric acid inhibition by Lansoprazole and Omeprazole in relation to meal administration. Digestive Disease and Sciences. 1997; 42(2):132–137.
2. Tang G, Serfaty-Lacronsniere C, Camilo ME, Russell RM. Gastric acidity influences the blood response to a beta-carotene dose in humans. Americal Journal of Clinicle Nutrition. 1996; 64(6):22–26.
3. Tolman KG, Sanders SW, Buchi KN, Karol MD,Jennings DE, Ringham GL. The effects of oral doses of Lansoprazole and omeprazole on gastric pH. Journal of Clinicle Gastroenterology. 1997; 24:65-70.
4. Fitton A, Wiseman L, Pantoprazole: A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs. 1996; 51:460–482.
5. Matheson AJ, Jarvis B. Lansoprazole: An update of its place in the management of acid-related disorders. Drugs. 2001; 61:1801–1833.
6. Bown RL. An overview of the pharmacology, efficacy, safety and cost-effectiveness of Lansoprazole. International Journal of Clinicle Practice. 2002; 56:132-139.
7. Karol MD, Granneman GR, Alexander K. Determination of Lansoprazole and five metabolites in plasma by ultra-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications. 1995; 9:182-186.
8. Singh S, Patel K, Agarwal VK, Chaturvedi S. Stability Indicating HPTLC Method for Simultaneous Determination of Valsartan and Hydrochlorothiazide in Tablets. International Journal of Pharmacy and Pharmaceutical Sciences. 2012; 4(4):68-471.
9. Singh S, Patel K, Agarwal VK, Chaturvedi S. Simultaneous estimation of S(-) Amlodipine Besylate Hemipentahydrate and Losartan Potassium in Combined Dosage Form by Using UV-Spectroscopy. Der Pharmacia Lettre. 2002; 4(3):897-905.
10. Singh S, Yadav AK, Gautam H. First Order Derivative Spectrophotometric Determination of Telmisartan in Pharmaceutical Formulation. Bulletin of Pharmaceutical Research. 2012; 2(2):83-86.
11. Singh S, Dubey N, Jain DK. Simultaneous estimation of cefpodoxime proxetil and clavulate potassium combined dosage form using UV-Spectroscopy and reverse phase liquid chromatography. International Journal of Biomedical and Pharmaceutical Sciences. 2011; 5(1):57-60.
12. Patel K, Singh S, Sahu P, Trivedi P. Development and validation of stability indicating assay method for naratriptan by ultra performance liquid chromatography. Der Pharmacia Lettre. 2011; 3(6):102-107.
13. Singh S, Yadav AK, Gautam H. Simultaneous Estimation of Valsartan and Hydrochlorothiazide in Solid Dosage Form Using UV Spectroscopy. Bulletin of Pharmaceutical Research. 2011; 1(3):10-12.
14. Singh S, Dubey N, Jain DK. Simultaneous Estimation of Atorvastatin, Clopidogrel and Aspirin in Capsule Dosage forms using UV-Spectroscopy. Asian Journal of Research in Chemistry. 2010; 3(4):885-887.

Published

01-07-2013
Statistics
Abstract Display: 330
PDF Downloads: 448
Dimension Badge

How to Cite

“VALIDATED RP-UPLC METHOD DEVELOPMENT FOR ESTIMATION OF LANSOPRAZOLE IN TABLET DOSAGE FORM”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 5, no. 3, July 2013, pp. 105-7, https://doi.org/10.25004/IJPSDR.2013.050305.

Issue

Volume 5, Issue 3, 2013

Section

Research Article

Copyright (c) 2013 Sunil Singh, Nisha Choudhary, Jyoti Rai, Inamullah ., Surabhi Sharma, Ajit Kumar Yadav, Hemendra Gautam, Shashank Chaturvedi, Vipin Kumar Agrawal

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

“VALIDATED RP-UPLC METHOD DEVELOPMENT FOR ESTIMATION OF LANSOPRAZOLE IN TABLET DOSAGE FORM”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 5, no. 3, July 2013, pp. 105-7, https://doi.org/10.25004/IJPSDR.2013.050305.